<DOC>
	<DOCNO>NCT02363855</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability BAY 1841788 Japanese subject metastatic castration-resistant prostate cancer ( mCRPC ) PK BAY 1841788 major metabolite BAY 1896953 .</brief_summary>
	<brief_title>Phase 1 Dose Escalation Study BAY 1841788 Japanese Metastatic Castration-resistant Prostate Cancer ( mCRPC ) Subjects</brief_title>
	<detailed_description>The drug product license Orion pharma , Finland also manufacturer product .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Japanese male age ≥ 20 year Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature Patients metastatic castrationresistant prostate cancer ( mCRPC ) . CRPC define follow Ongoing androgen deprivation therapy luteinizing hormonereleasing hormone ( LHRH ) analogue antagonist , bilateral orchiectomy , castrate level serum testosterone ( &lt; 1.7 nmol/l [ 50 ng/dL ] ) screening AND Progressive disease and/or prostatespecific antigen ( PSA ) increase three consecutive rise , least 1 week apart AND PSA &gt; 2ng/mL screen Eastern Cooperative Oncology Group performance status ( ECOG PS ) 01 Life expectancy least 3 month Blood count screening : haemoglobin ≥ 9.0 g/dL , absolute neutrophil count ≥ 1,500/μL ( 1.5x109/l ) , platelet count ≥ 100,000/μL ( 100x109/l ) ( patient must receive growth factor blood transfusion within 7 day hematology laboratory obtain screen ) Screening value serum alanine aminotransferase ( ALT ) and/or aspartate transaminase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) , total bilirubin ≤ 1.5 x ULN , creatinine ≤ 1.5 x ULN , albumin &gt; 3.0 g/dl Prior treatment antiandrogen . Discontinuation bicalutamide nilutamide ( approve Japan ) least 6 week antiandrogens least 4 week prior start study drug administration . Known metastasis brain Symptomatic localregional disease require medical intervention include moderate/severe urinary obstruction hydronephrosis due prostate cancer Acute toxicity ( except alopecia CTCAE grade 2 neuropathy ) prior treatment procedure resolve CTCAE ≤ grade 1 baseline first drug administration Febrile neutropenia Common Terminology Criteria Adverse Events ( CTCAE ) ≥ 3 History malignancy within previous 5 year except basal cell carcinoma skin cancer treatment complete ≥ 5 year ago patient diseasefree5 year ago patient diseasefree Prior treatment within 4 week first drug administration immunotherapy , antiandrogen , CYP17 inhibitor ( CYP17i ) , oral ketoconazole , estrogens , 5α reductase inhibitor investigational treatment Use bicalutamide nilutamide ( approve Japan ) within 6 week first drug administration Radiation therapy ( external beam radiation therapy [ EBRT ] , brachytherapy , radiopharmaceutical ) chemotherapy ( except nitrosoureas mitomycin C ) within 4 week first drug administration . Use nitrosoureas mitomycin C within 6 week first drug administration . Prior use herbal product know decrease PSA level ( e.g . PC SPES saw palmetto ) within 4 week first drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
	<keyword>Castration-resistant prostate cancer ( CRPC )</keyword>
</DOC>